A Randomized, Double-Blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis. J of Skin 2021, 5 (6), s94. https://doi.org/10.25251/skin.5.supp.94.